Storage and handling
Room temperature (68° to 77°F, 20° to 25°C) Avoid excessive heat. Protect from freezing.
Room temperature (68° to 77°F, 20° to 25°C) Avoid excessive heat. Protect from freezing.
ACD-A 50 mL
Catalog # AMSACD-A
Anticoagulant intended for use only with devices that prepare Platelet Rich Plasma (PRP) products for extracorporeal use. See Operator's Manuals for additional information and complete usage instructions.
Sterile. Non-pyrogenic. Do not use unless the solution is clear and the container is intact and undamaged.
Rx only. Single use container.
Not for preparation of blood products for transfusion or for direct intravenous infusion.
Room temperature (68° to 77°F, 20° to 25°C)
Avoid excessive heat. Protect from freezing.
| Citric Acid Monohydrate USP | 0.08 g |
| Sodium Citrate Dihydrate USP | 0.220 g |
| Dextrose Monohydrate USP | 0.245 g |
| In Water for Injection USP |
Manufactured for Arteriocyte Medical Systems, Inc.
45 South Street, Hopkinton, MA., 01748
by Ivex Pharmaceuticals, Larne, BT40 2SH, UK.
ARTERIOCYTE
CELLULAR THERAPIES
MEDICAL SYSTEMS
Lot
Expiry Date
Anticoagulant Citrate Dextrose Solution,
Solution A USP ACD-A
50 mL
50 x 50 mL
Catalog # AMSACD-A
Anticoagulant intended for use only with devices that prepare Platelet Rich
Plasma (PRP) products for extracorporeal use. See Operator's Manuals for
additional information and complete usage instructions.
Sterile. Non-pyrogenic. Do not use unless the solution is clear and the
container is intact and undamaged. Rx only. Single use container.
Caution: Not for preparation of blood products for transfusion or for direct
intravenous infusion.
Storage Conditions: Room temperature (68° to 77°F, 20° to 25°C)
Avoid excessive heat. Protect from freezing. Protect from direct sunlight.
Each 10mL contains:
Citric Acid Monohydrate USP
0.08 g
Sodium Citrate Dihydrate USP
0.220 g
Dextrose Monohydrate USP
0.245 g
In Water for Injection USP
Manufactured for Arteriocyte Medical Systems, Inc.
45 South Street, Hopkinton, MA., 01748
by Ivex Pharmaceuticals, Larne, BT40 2SH, UK.
ARTERIOCYTE
CELLULAR THERAPIES
MEDICAL SYSTEMS
Lot
Expiry Date

| Class | Version | Type | Effective |
|---|---|---|---|
| ANHYDROUS CITRIC ACID Pharmacologic Class Indexing | 3 | Indexing - Pharmacologic Class | 20180813 |
| SODIUM CATION Pharmacologic Class Indexing | 2 | Indexing - Pharmacologic Class | 20180813 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 43203-852-47 | Anticoagulant Citrate Dextrose A ACD-A | 1 in 1 POUCH | INJECTION, SOLUTION | 1 | 4 | |
| 43203-852-47 | Anticoagulant Citrate Dextrose A ACD-A | 50 in 1 CASE | INJECTION, SOLUTION | 50 | 4 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| CITRIC ACID MONOHYDRATE | ACTIVE INGREDIENT | 2968PHW8QP | 2 | |
| DEXTROSE MONOHYDRATE | ACTIVE INGREDIENT | LX22YL083G | 2 | |
| SODIUM CITRATE | ACTIVE INGREDIENT | 1Q73Q2JULR | 2 | |
| ANHYDROUS CITRIC ACID | ACTIVE MOIETY | XF417D3PSL | 2 | |
| ANHYDROUS DEXTROSE | ACTIVE MOIETY | 5SL0G7R0OK | 2 | |
| SODIUM CATION | ACTIVE MOIETY | LYR4M0NH37 | 2 | |
| Water | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 43203-852 | 43203-852-47 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | ACTIM |
| SODIUM CITRATE, UNSPECIFIED FORM | 1Q73Q2JULR | ACTIB |
| DEXTROSE MONOHYDRATE | LX22YL083G | ACTIB |
| Water | 059QF0KO0R | IACT |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Anticoagulant Citrate Dextrose A ACD-A | ANTICOAGULANT CITRATE DEXTROSE A ACD-A | Arteriocyte Medical Systems, Inc. | b850deac-161f-4bb0-ac7f-bceac2a230c0 | 2025-01-23 | 43203-852-47 43203-852 43203085247 49c60185-a86d-44a7-a10e-d0ec57df1fbe b850deac-161f-4bb0-ac7f-bceac2a230c0 |
Adverse event summaries are temporarily unavailable. Other product information remains available.